Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma
Recruitment status was Active, not recruiting
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue.
PURPOSE: Phase I trial to study the effectiveness of boron neuron capture therapy in treating patients with stage III melanoma.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||PROCEDURES FOR BNCT PHASE-I STUDY OF MELANOMA IN THE EXTREMITIES|
|Study Start Date:||April 1996|
OBJECTIVES: I. Estimate the maximum tolerated dose of neutron irradiation that can be given in combination with borophenylalanine-fructose complex (BPA-F) in patients with stage III melanoma. II. Evaluate the safety of this regimen. III. Evaluate tumor response to this regimen.
OUTLINE: This is a dose-finding study. Patients receive a test dose of borophenylalanine-fructose complex (BPA-F) for biodistribution studies and undergo punch biopses of tumor and normal tissue to measure B-10 concentration. Later, a treatment dose of BPA-F over 1 hour is followed by neutron irradiation. Groups of 3 patients receive escalated doses of neutron irradiation until the maximum tolerated dose is determined. Patients who complete protocol treatment and continue to meet the eligibility criteria may re-enter the study, provided at least 6 months has elapsed since the completion of prior therapy and the field boundary for the new irradiation site is seperated from the boundary of the previously irradiated site. Patients are followed monthly for 12 months, then every 3-6 months as needed.
PROJECTED ACCRUAL: Approximately 15 patients will be entered.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002781
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Boston University School of Medicine|
|Boston, Massachusetts, United States, 02118|
|Study Chair:||Paul M. Busse, MD, PhD||Beth Israel Deaconess Medical Center|